Research Aesthetic Surgery Journal Commentary 2018, Vol 38(2) 211 © 2017 The American Society for Aesthetic Plastic Surgery, Inc. Commentary on: Adipose-Derived Stem Reprints and permission: email@example.com Cells in Aesthetic Surgery: A Mixed Methods DOI: 10.1093/asj/sjx177 www.aestheticsurgeryjournal.com Evaluation of the Current Clinical Trial, Intellectual Property, and Regulatory Landscape Afshin Mosahebi, MBBS, FRCS, MBA, PhD, FRCS (Plast) Editorial Decision date: September 1, 2017; online publish-ahead-of-print October 31, 2017. Adipose-derived stem cells (ADSC) continue to incite con- Disclosures troversy in the medical profession, are highly sought after The author declared no potential conflicts of interest with by the public, incite excitement in commercial companies, respect to the research, authorship, and publication of this and are seen as a lucrative income generator in clinics. article. This interesting analysis of ADSC registered trials as well Funding as registered intellectual properties further illustrates these points. The author received no financial support for the research, The article confirms the paucity of good quality trials, authorship, and publication of this article. despite 1250 registered ones, almost none seem to plan long-term follow up of the effect. Additionally, there is no REFERENCE agreed standard methodology of assessment of the quality 1. Arshad Z, Halioua-Haubold CL, Roberts M, et al. Adipose- of the ADSC. This is in spite of the large number of patents Derived Stem Cells in Aesthetic Surgery: A Mixed Methods put in for separation and concentration technologies, as Evaluation of the Current Clinical Trial, Intellectual well as innovative applications. Property, and Regulatory Landscape. Aesthet Surg J. The explanation of regulatory landscape is very enlight- 2018;38(2):199–210. ening, illustrating the great deal of variability in different continents. In some cases, vagueness and lack of clarity in regulation has enabled potential unscrupulous misin- terpretations and misuses false promotion of services. An exemplar regulation is in Japan, where there is a specific section for regenerative medicine. This not only helps to promote innovation and genuine effect and uses, but also reduces the back-street rogue clinics and should be Prof Mosahebi is a Consultant Plastic Surgeon, Department of Plastic Surgery, Royal Free Hospital, London, United Kingdom. a lesson to regulatory bodies in the United States and European Union. Corresponding Author: This unique article gives ASJ readers a comprehensive Prof Afshin Mosahebi, Department of Plastic Surgery, Royal Free overview of global landscape in ADSC field, trials, and Hospital, NW3 2QG London, United Kingdom. E-mail: firstname.lastname@example.org regulation. Downloaded from https://academic.oup.com/asj/article-abstract/38/2/211/4583508 by Ed 'DeepDyve' Gillespie user on 16 March 2018
Aesthetic Surgery Journal – Oxford University Press
Published: Feb 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera